Related Experiment Video
Updated: Aug 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Anemia in patients on combined androgen block therapy for prostate cancer
Li-Xin Qian1, Li-Xin Hua, Hong-Fei Wu
1Department of Urology, First Affiliated Hospital, Nanjing Medical University, 210029,China. qianlx@jlonline.com.
Aim:
To study the effect of combined androgen block therapy on hemoglobin and hematocrit values in patients with prostate cancer.
Methods:
One hundred and thirty-six patients with adenocarcinoma of prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, tid). Complete blood counts were determined before and after 1, 2, 3, 6, 9 and 12 months of therapy.
Results:
The hemoglobin and hematocrit levels declined significantly in all patients and at all the time points after treatment (P<0.05).
Conclusion:
Prostate cancer patients treated with combined androgen block would develop obvious anemia. Recombinant human erythropoietin can be used to treat patients with severe anemia.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors
Nursing Assessment of the Genitourinary System I: Health History
